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Aims: The study compared performance of nanoparticles from synthetic organic, natural organic and 
inorganic materials as vaccine delivery platforms. 
Methods: Various formulation (concentration, polymer/silica: surfactant ratio, solvent) and process 
parameters (homogenization speed and time, ultra-sonication) affecting functional performance 
characteristics of poly(lactic-co-glycolic acid) (PLGA), chitosan and silica based nanoparticles 
containing bovine serum albumin were investigated. Nanoparticles were characterised using dynamic 
light scattering, X-ray diffraction, scanning/transmission electron microscopy, Fourier transform 
infrared spectroscopy and in vitro protein release.  
Results: Critical formulation parameters were surfactant concentration (PLGA, silica) and polymer 
concentration (chitosan). Optimised nanoparticles were spherical in shape with narrow size distribution 
and size ranges of 100-300 nm (blank) and 150-400 nm (protein loaded). Protein encapsulation 
efficiency was 26-75% and released within 48 hours in a sustained manner.  
Conclusion: Critical formulation and process parameters affected size of PLGA, chitosan and silica 
nanoparticles and protein encapsulation, whilst silica produced the smallest and most stable 
nanoparticles.       
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1 Introduction  
In the last decade, advancements in nano-engineering and material science, have made nanoparticles 
very attractive and have been widely investigated in the field of drug delivery and nanomedicine[1] [2].  
Nano carriers might help to deliver therapeutic proteins via the oral route due to two main 
characteristics: (i) as a protective shield against the harsh host biological environment and (ii) as a 
carrier to cross the mucosal epithelia (membrane) in the gastrointestinal tract (GIT) [3]. Recently, 
polymeric nanoparticles have received increased attention in oral protein delivery due to their stability, 
biodegradability, and biocompatibility in biological systems and ease of surface modification to suit 
various applications [4] as well as ability to protect therapeutic proteins against enzymatic (e.g. 
nucleases and proteases) degradation [5]. Protein encapsulation in polymeric nanoparticles is a very 
challenging but promising area in protein delivery research [6] [7], therefore fundamental and 
systematic formulation development and optimization of selected delivery systems to reach the intended 
site of action is an important endeavour. 
Poly(D,L-lactide-co-glycolide) or poly(lactic-co-glycolic acid) (PLGA) is one of the most 
widely used polymers for formulating nanoparticle carriers in protein/peptide oral delivery [8]. The 
Food and Drugs Administration (FDA) and European Medicine Agency (EMA) approved poly-lactic-
co-glycolic acid (PLGA) for various drug delivery applications such as blends, films, matrices, 
microspheres, pellets and nanoparticles [9]. PLGA nanoparticles have been proven to be capable of 
encapsulating and protecting protein molecules against harsh biological environments, allow sustained 
release and improve their therapeutic efficacy [10]. Since 1990, chitosan has been studied as drug 
delivery material in the form of film forming matrices for controlled release of drugs with the ability to 
temporally open intracellular epithelial tight junctions and facilitate uptake of hydrophilic drugs [11]. 
In the mid to late 1990s, a new self-assembling amphiphilic form of chitosan was introduced for 
formulating chitosan nanoparticles [12]. To determine and characterize the functional properties of 
chitosan, molecular weight, polydispersity and degree of deacetylation are important factors which 
greatly affect the particle size, particle formation and aggregation [12]. Various researchers have 
reported the formulation of chitosan nanoparticles as protein delivery carrier to protect entrapped 
proteins from enzymatic degradation in biological systems [13][14][15]. One of the major advantages 
of chitosan is its ability to form positively charged particles under mild agitation conditions without the 
need for harmful organic solvents and facilitate the adsorption or encapsulation of therapeutic proteins 
and antigens or form polyplexes by electrostatic interaction with negatively charged nucleotides [16]. 
Mesoporous silica nanoparticles (MSNs) are a class of molecules that have attracted attention in the 
delivery of small molecules, due to their many desirable properties. They are easily synthesised with 
open pore structure, and the size of the pores and particle surface can be controlled during synthesis 
[17]. Furthermore, the silanol-containing surface of silica nanoparticles can be easily functionalized 
with bio-recognition entities which allows targeting of specific cells or receptors in the body [18]. Due 
to their mesoporous structure, silica nanoparticles can easily encapsulate protein molecules and protect 
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them from harsh biological environments in the body, thereby increasing the efficiency of protein 
delivery, reducing renal clearance and ultimately increasing duration of action [19]. Since silica 
nanoparticles are much smaller than eukaryotic cells, they allow the use of protein transport in the 
cytosol via an endocytosis pathway and subsequent endosomal escape [20]. 
The aim of this study was the formulation development and subsequent comparison of 
nanocarriers obtained from three different types of materials (i) synthetic polymer (PLGA), (ii) 
biomaterial organic polymer (chitosan) and (iii) inorganic (silica). In addition we have investigated 
bovine serum albumin (BSA) encapsulation as a model protein with special emphasis on important 
physicochemical properties and processing parameters to achieve optimised characteristics for both 
polymeric and inorganic nanoparticles that will be suitable for potential mucosal vaccination. Though 
various studies have investigated the use of individual synthetic, natural or inorganic based 
nanoparticles for protein delivery, no study has systematically compared nanoparticles obtained from 
different sources for protein encapsulation in a single study. Therefore the novelty of the study lies in 
the fact that, to the best of our knowledge, this is the first study that systematically compares 
nanoparticles obtained from synthetic organic (PLGA), natural organic (chitosan), and inorganic 
starting materials and simultaneously investigating the effect of process and formulation variables on 
the performance characteristics of the resulting nanoparticles for potential protein delivery. 
 
2 Materials and Methods 
2.1 Materials 
Poly(D,L-lactide-co-glycolide) lactide: glycolide (50:50), MW 30,000-60,000 (Lot, P2191),  chitosan 
(medium molecular weight, 75-85% deacetylated, lot no 448877),  poly (vinyl alcohol) MW 89000-
98000, 99+% hydrolysed tetraethyl orthosilicate, MW 208.33,  cetyltrimethylammonium bromide, 
MW 62,000,  Tween 80  average MW 1310,  Pluronic® F-127 CAS N0: 9003-11-6, sodium 
tripolyphosphate, and bovine serum albumin were purchased from  Sigma-Aldrich, (Gillingham, UK).  
Glacial acetic acid,  calcium chloride (CaCl2), Coomassie brilliant blue, disodium hydrogen phosphate 
(Na2HPO4),  hydrochloric acid (HCl), monobasic potassium dihydrogen phosphate (KH2PO4), sodium 
acetate, sodium azide (NaN3),  sodium bicarbonate (NaHCO3), sodium chloride (NaCl) , sodium 
chloride (NaCl), sodium dihydrogen phosphate, NaH2PO4, sodium hydroxide (NaOH), and D(+) 
trehalose were purchased from (Thermo Fisher Scientific, Loughborough, UK).   
 
2.2 Formulation development 
2.2.1 Preparation of PLGA nanoparticles  
PLGA nanoparticles were prepared by solvent emulsification evaporation and double emulsion (w/o/w) 
technique as previously reported [21] but with some modifications. Briefly, 100mg PLGA was 
dissolved in 5ml dichloromethane (DCM) and vortexed until a clear solution was obtained, 0.5 ml 
phosphate buffered saline (pH 7.4) was added and sonicated for 30 s at amplitude of 70% to obtain a 
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primary emulsion. Different amounts of polyvinyl alcohol (PVA) were dissolved in 100ml of deionised 
water and the temperature increased up to 60ºC with stirring at 300rpm for 30 min until a clear solution 
(1 - 4% w/v) was obtained and then cooled to room temperature. The primary emulsion was added 
dropwise into 50ml of the 1% w/v PVA and sonicated as described above and this was repeated for the 
other PVA (2%, 3% and 4% w/v) solutions respectively. The DCM was then evaporated by stirring 
continuously on a magnetic stirrer at 300rpm for 6 hrs. Homogeneous nanoparticles were obtained with 
the help of a homogenizer at different speeds (1000 – 10,000 rpm) and duration (5 – 25 min) of stirring. 
The procedure was repeated for two other surfactants (Tween 80 – TW and Pluronic F127 - PL) in place 
of PVA. The final formulated nanoparticle emulsion was centrifuged at 15000 rpm for 30 min, pellet 
collected, washed 3 times with deionized water, freeze dried and characterized as a blank nanoparticle. 
To obtain protein loaded nanoparticles, freeze dried blank nanoparticles were dispersed in deionized 
water, 20mg/ml of bovine serum albumin (BSA) solution was added dropwise into 80ml of dispersed 
lyophilized PLGA nanoparticle suspension to achieve a final volume of 100ml and sonicated for 60 s 
whilst placed on ice to avoid heat generation in the solution. Finally, protein loaded nanoparticles were 
centrifuged at 15000 rpm for 30 min and both supernatant and pellet were collected to analyse the 
amount of protein encapsulation in the nanoparticle and free protein in the supernatant.   
 
2.2.2 Preparation of chitosan nanoparticles  
Chitosan nanoparticles were prepared by following inotropic gelation method [22] using medium 
molecular weight chitosan. Chitosan was dissolved in an aqueous solution of acetic acid (1% v/v) at 
different chitosan concentrations (Figure S1, Supplementary data) and allowed to fully dissolve (60 
min). Then 1mg /ml sodium tripolyphosphate (TPP) solution was added dropwise to the chitosan 
solution with magnetic stirring (600rpm). The blank nanoparticles were formed during stirring at room 
temperature of chitosan-TPP suspension for 60 min and sample collected as blank nanoparticles for 
characterisation. Protein loaded chitosan-TPP nanoparticle suspensions were prepared by simply adding 
the BSA solution (0.5mg/ml) without adding any organic solvents or high energy (e.g. sonication) 
sources. The BSA loaded chitosan-TPP nanoparticle suspension was gently stirred for 4 hrs at room 
temperature and the resulting particles collected for further analysis. The incorporation technique 
described were used to prepare a total of 4 different protein loaded nanoparticle formulations using the 
above experimental variables (i.e. chitosan-TPP ratio) described for the blank equivalents.    
 
2.2.3 Preparation of silica nanoparticles  
Silica nanoparticles were prepared by sol-gel synthesis process with slight modification [23]. 2ml of 
tetraethylorthosilicate (TEOS) and 2ml HCl (0.0035M) were mixed together and stirred for 30 min 
under ambient temperature, sonicated for 30 s and then stirred again for 2 hrs until it became transparent. 
After that, pre-determined amounts (0.1% - 1.0%) of cetyltrimethylammonium (CTAB) surfactant 
solutions were added separately. The TEOS and surfactant solutions were stirred at 80°C for 2 hrs, till 
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a solid white precipitate was obtained. The temperature was reduced slowly and the white precipitate 
centrifuged (15,000 × rpm) to separate out the solid blank nanoparticles. The white product was washed 
four times, (once with ethanol and three times with Millipore deionized water). The ethanol washing 
was done to remove excess amounts of surfactants. After centrifuging, the blank silica nanoparticles 
were dispersed in 80 ml deionized water and stirred for 1 hr. 20ml of BSA (5mg/ml) solution was added 
slowly into the resulting blank silica nanoparticles suspension and stirred cold at room temperature for 
24 hrs to prepare protein loaded nanoparticles. The BSA loaded mixture was centrifuged at 15000× rpm 
(Hitachi) and supernatant separated from pellet and free protein concentration in the supernatant 
analysed using Bradford protein assay.  
  
2.3 Protein encapsulation and loading studies 
After overnight incubation, protein-loaded PLGA, chitosan and silica nanoparticles were collected by 
centrifugation (15000 rpm, 30 min) and separated from the non-encapsulated (free) BSA. BSA 
concentration was calculated from Bradford assay using the equation of a calibration curve. This was 
achieved by measuring the fluorescence intensity and absorbance of BSA solutions loaded in 96-well 
plates with the help of a plate reader (Thermofisher multiskan, photometer). The standard curves were 
based on the absorbance of protein within the concentration range of 0.1mg/ml to 3mg/ml. The 
calibration curves were based on the absorbance at 620 and 540, respectively, as a function of 
concentration. The EE % and loading capacity (mg/g) were calculated as shown in equations 1 & 2.  
𝐄𝐄(%) =
𝐭𝐨𝐭𝐚𝐥 𝐚𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐁𝐒𝐀−𝐟𝐫𝐞𝐞 𝐁𝐒𝐀 𝐢𝐧 𝐬𝐮𝐩𝐞𝐫𝐧𝐚𝐭𝐞𝐧𝐭 
𝐭𝐨𝐭𝐚𝐥 𝐚𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐁𝐒𝐀
× 𝟏𝟎𝟎    (1) 
𝐋𝐂(%) =
𝐭𝐨𝐭𝐚𝐥 𝐚𝐦𝐨𝐮𝐧𝐭 𝐨𝐟 𝐁𝐒𝐀−𝐟𝐫𝐞𝐞 𝐁𝐒𝐀 𝐢𝐧 𝐬𝐮𝐩𝐞𝐫𝐧𝐚𝐭𝐞𝐧𝐭
𝐃𝐫𝐢𝐞𝐝 𝐧𝐚𝐧𝐨𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬 𝐰𝐞𝐢𝐠𝐡𝐭 
× 𝟏𝟎𝟎    (2) 
 
2.3.1 Limit of detection (LOD) and limit of quantitation (LOQ) 
LOD and LOQ were calculated from the data obtained from the linearity plot. For each of the three 
replicate determinations of same concentration, standard deviation (SD) of the responses was 
calculated. 









Where α = Standard deviation of the response; S = Slope of the calibration curve. 
Range of 100-2000 µg/ml, linear regression (LR) Y=0.4625x +0.7656, R2= 0.9978, LOD=0.2 µg/ml 





2.4 Formulation process optimisation 
Different parameters that affect the functional properties of the nanoparticles were investigated as part 
of formulation development and optimization process. 
2.4.1 Concentration of polymer/silica and surfactant ratio 
To determine the optimum surfactant concentration in aqueous phase during the PLGA nanoparticle 
preparation, three different types of surfactants (polyvinyl alcohol-PVA, Pluronic-PL and Tween 80-
TW) were used and different surfactant concentrations (0.1%, 0.5%, 1% and 1.5% w/v) were also 
prepared and their effect on nanoparticle size, polydispersity index (PDI) and zeta potential measured. 
To determine the chitosan and TPP ratio, different concentrations of chitosan (0.1%, 0.2%, 0.3% and 
0.4%) were formulated at fixed amount of TPP 1mg/ml. For silica nanoparticles, CTAB was employed 
at different concentrations from (0.1% - 1.0%) with fixed amount of TEOS 2ml (v/v).  
2.4.2 Effect of homogenizer speed and sonication time.  
Different formulation batches were prepared at various homogenization speeds (1000, 3000, 5000, 7000 
and 10000rpm) respectively and their sizes, PDI and zeta potential were measured. Sonication was 
performed at different amplitudes (30%, 40%, and 50%) and over different time periods (1 – 12 min) 
and the effect on particle size, PDI and zeta potential evaluated. 
 
2.5 Physicochemical characterization of nanoparticle properties 
2.5.1 Particle size evaluation using dynamic laser scattering (DLS) 
Particle size, polydispersity index and zeta potential were measured using a Zetasizer Nano-ZS90 
(Malvern Instruments, UK). Disposable sizing cuvettes were used for size and PDI analysis while zeta 
potential were measured using a reusable folded capillary Zeta Cell, Malvern Model: DTS1070. The 
samples was measured in double distilled water and adjusted to a conductivity of 50 IS/cm with sodium 
chloride solution (0.9% w/v). The pH was in the range of 5.5-7.5 and the applied field strength was 20 
V/cm.  The measurements were made at a position of 4.65 mm from the cuvette wall with an automatic 
attenuator and at a controlled temperature of 20°C. All the measurements were performed in triplicate 
(n = 3) and data were presented as mean ± SD.       
2.5.2 Morphology by scanning and transmission electron microscopy 
The morphology of the PLGA, chitosan and silica nanoparticles was examined by scanning electron 
microscopy (SEM) (Hitachi SU8030) at operating voltage of 1kV. One drop of freshly prepared particle 
suspensions was deposited on sample stub, allowed to dry in air and the air dried sample was coated 
with chromium for 3 min. Low voltage (1 kV) was set for observing PLGA nanoparticles to avoid 
heating by strong electron stream which caused particle deformation and decomposition. Further a high 
resolution transmission electron microscope (TEM) was used to examine morphological characteristic 
of nanoparticles. One drop of sample was placed on 300 mesh copper grid, allowed to sit for 10 min 
until air dried and excess liquid removed using filter paper before observation on the TEM machine. 
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For scanning transmission electron microscopy (STEM) analysis, 30 kV high-resolution instrument was 
used to examine morphological characteristic of nanoparticles.   
2.5.3 Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectroscopy  
The infrared spectra were obtained for both pure starting materials and the various nanoparticles at 20°C 
for wavenumbers ranging from 4000-450 cm–1. ATR-FTIR analyses were performed in absorption 
mode using a Perkin Elmer FT-IR spectrophotometer. Different peaks in the IR spectrum were 
interpreted for different functional groups in the formulations.    
2.5.4 X-ray diffraction (XRD) 
X-ray diffraction was performed to investigate crystalline or amorphous nature of the formulated 
nanoparticles. The diffractograms were recorded using a Bruker AXS D8 Advance instrument with Cu-
ka line as a source of radiation and operated at a voltage of 40 keV and current of 35 mA. Freeze dried 
formulated samples and pure starting materials were measured in a 2θ range between 3º and 80º for 10 
min at a step size of 5 s. 
2.5.5 In-vitro protein release study 
To determine the amount of protein released from PLGA, chitosan and silica nanoparticles, the Bradford 
reagent (protein-specific dye, Coomassie brilliant blue) was used and analysed in a 96-well polystyrene 
plate. Freeze dried protein loaded nanoparticles (5mg|) were dispersed in 0.01% sodium azide 
containing 2ml of PBS (pH 7.4) and incubated at 37°C in bath shaker with gentle stirring. At pre-
determined time intervals over 48hrs, 0.1ml aliquots of dissolution medium were collected and replaced 
with same amount of fresh PBS. The samples (n = 3) were analysed with absorbance plate reader at 
wavelength of 595nm and Bradford reagent standards were used according to manufacturer’s 
instruction kit.  
2. 6 Statistical analysis 
All the quantitative data from DLS and protein analyses were analysed by one-way ANOVA using 
GraphPad Prism software (version 5.02). The level of significance was set at p < 0.05. 
 
3 Results and discussion:  
3.1 Effect of concentration of polymer, silica and surfactant on particle properties.   
The various formulation and process parameters (nanoparticle size, zeta potential, PDI, morphology 
and emulsion composition) were considered in order to select the optimum formulation(s) for 
encapsulating proteins as well as comparing the performance characteristics of optimised PLGA, 
chitosan and silica nanoparticles. Generally, the optimised PLGA, chitosan and silica nanoparticles had 
size below 300nm as was originally intended (Figure 1). The results (Figure S1) showed that the amount 
of stabilizing agent and polymer affected the particle size, PDI and zeta potential of PLGA 
nanoparticles. The DLS results for PLGA-PVA formulations showed that when PVA amount increased, 
size decreased, and zeta potential increased which can be attributed to the increased ability of the 



















homogenization. It is well established that nanoparticle surface charge also plays a vital role to interact 
with target cells upon administration and the PLGA nanoparticles showed a negative surface charge 





















Figure 1. Figure 1 DLS results showing (A) particle size, (B) PDI and (C) zeta potential of selected 
optimised nanoparticles prepared with poly(lactic-co-glycolic acid)-polyvinyl alcohol (PLGA-PVA), 
chitosan-sodium tripolyphosphate (TPP) and silica (SNPs) (n = 3) 
 
Higher concentrations of surfactant resulted in better stabilized nanoparticles with desirable size and 
surface charge properties was not affected. It was also observed that, generally, the PDI of the PLGA 
nanoparticles was low which indicates narrow size distribution, and this was also influenced by the 
surfactant ratio. For PLGA and PL based formulations, at 0.1% to 1.5% surfactant content, the PDI 
decreased (p < 0.05) from 0.52 ± 0.2, to 0.12 ± 0.2 respectively. Increasing the amount of TW from 
0.1% to 1.5% also increased (p < 0.05) the particle diameter from 266 ± 6 nm to 309 ± 10 nm.  In this 
case two factors were involved: a) when organic phase (PLGA/DCM) was added dropwise into the 
aqueous phase (surfactant solution), the solution became more viscous and reduced the net shear stress 
with possibility to make bigger droplets; b) when viscosity increased in surfactant solution, there was a 












































nanoparticles prepared from emulsions containing 1% and 1.5% concentrations of PVA (surfactant) 
were selected for protein encapsulation.   
Nanoparticles from chitosan were successfully formed through ionic gelation of chitosan with 
TPP acting as the cross-linking moiety. The process yielded homogenously dispersed nanoparticles 
>100 nm in size, with low PDI and generally high zeta potential values via a simple and easily 
reproducible method. The chitosan-TPP nano systems demonstrate a wide range of attractive features 
which render them promising as carriers of oral protein delivery [12, 24]. For chitosan nanoparticles, 
the particle size was linearly increased (p < 0.05) from 221nm to 346nm by increasing chitosan 
concentration from 0.1% to 0.4%, possibly due to presence of intermolecular hydrogen bonding (-OH) 
and intermolecular electrostatic repulsion with -NH3+ which exist on the chitosan surface [25].  
When chitosan concentration was increased from 0.1% to 0.4% (Figure S3, supplementary 
data) there was slight increase (p > 0.05) of zeta potential from +26 to +29mV except 0.2% formulation. 
This is because, the positive surface charge on chitosan -TPP nanoparticle does not interact with TPP 
ions due to the presence of residual amine groups [22]. The slight decrease of zeta potential value +26 
to +24 mV on 0.2% could be caused by the H+ liberated from the acetic acid (CH3C00-H+) which had 
been used up to protonate the NH2 groups on the backbone of chitosan to allow the polymer to fully 
dissolve during formulation [26].  Similarly, when chitosan concentration increased from 0.1% to 0.4%, 
the PDI also increased (p < 0.05) from 0.19 to 0.27 due to the fact that higher concentration tends to 
increase the agglomeration of particles which in turn prompt an increased polydispersity of the particles 
(Figure S2). Overall, nanoparticles obtained from chitosan: TPP ratio of 1:1 with 0.1% total chitosan, 
showed good particle size, PDI and zeta potential values.   
From the DLS measurement it was observed that, silica nanoparticles were not formed 
effectively at CTAB concentrations from 0.1% to 0.5%. The PDI values of these formulations (silica 1 
to silica 5) were high (0.6 to 0.4) due to the absence of monodispersed particles and dispersion solution 
not being homogenous. The particles size ranged from 1000nm to 3000nm for silica 1 to silica 5 samples 
(FigureS3, supplementary data), while zeta potential values indicated low stability of particles in 
solution. At higher concentration (0.6%) of CTAB nano sized particle formation was observed with 
mean particles size in the range of 230 to 650 nm. Monodisperse particles with uniform size of 132 ± 2 
nm was observed for the silica 9 sample prepared with CTAB concentration of 0.9% and was chosen 
as optimum concentration for protein loading. However, the formulations obtained from CTAB 
concentrations of 0.9% and 1%, showed larger particle sizes under the same experimental conditions 
due to particle agglomeration.  
 
3.2 Effect of homogenizer speed and duration on nanoparticle size, PDI and zeta potential.   
In addition to the concentration of starting materials, homogenizer speed and total time of mixing also 
affected the size, PDI and zeta potential of all the three types (PLGA, chitosan and silica) of 
nanoparticles. In Figure 2 it was observed that the homogenizer speed had a remarkable effect on PLGA 
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nanoparticle size and dispersion, with particle size decreasing and PDI increasing as the homogenizer 
speed increased. At low homogenizer speed (1000rpm) over 10 min, the size was 2547 ± 152 nm, PDI 
0.93 ± 0.4 and zeta potential -8.40 ± 3.8 mV. However, increasing the homogenizer speed gradually to 
10000 rpm at fixed time of stirring (P5) showed a significant (p < 0.05)) reduction in particle size to 
290 ± 7, PDI to 0.10 ± 0.1 while zeta potential increased to -12 ± 6.8. Further, Figure S4 and S5 
(supplementary data) show effects of homogenizer speeds below 10,000 and effect of homogenizer 
speed at fixed time respectively on properties of PLGA nanoparticles. The faster the suspension was 
stirred, the more stable the particles appeared based on the zeta potential. Increasing high shear stress 
leads to the formation of smaller particles resulting in repulsive forces between the similarly charged 
particles, preventing their aggregation and therefore increase in their stability. For a fixed stirring speed, 
the particle size decreased and zeta potential increased with increasing homogenizer stirring time. 
Furthermore, the data also shows that the optimum stirring speed and time were 10000 rpm and 25 min 
respectively because above these values, the suspension begins to foam and generated a lot of air 




































































Figure 2: Investigation of effect of homogenizer time at fixed stirring speed (10,000 rpm) for blank 
poly(lactic-co-glycolic acid)-polyvinyl alcohol (PLGA-PVA), chitosan- sodium tripolyphosphate 
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 Different homogenization speeds were employed in a representative chitosan nanoparticle 
formulation (0.1%) prepared from chitosan 100mg and 0.1% TPP. Narrow and small size range of 
nanoparticles diameter was obtained at 7000rpm in 10 min which was selected as homogenizer speed 
for further investigation. Homogeniser speeds beyond 7000 caused the nanoparticle formulations to 
form bubbles and overflowed, which caused spillage. When homogenization speed increased from 1000 
to 7000 rpm in 10 min (Figure S4, supplementary data), the overall average diameter of the 
nanoparticles was reduced from 325 ± 1 to 277 ± 4nm. Figure S5 to S9 (supplementary data) shows the 
effect of homogenizer at same speed for different time intervals on behaviour of chitosan nanoparticles.  
Increasing time of homogenization further from 10 min to 25 min caused nanoparticles size to be 
reduced, however, this again caused bubble formation. Chitosan showed consistent and reproducible 
formulation in the terms of size distribution of nanoparticles, but high shear force greatly impacted 
polydispersity and zeta potential values. However, considering the effect of homogenization speed and 
time, on the results based on distribution of particle size, method consistency and production yield, it 
was difficult to determine the optimum formulation. As a result of the uncertainty about the optimum 
formulation, all four formulations were selected for protein loading and in vitro process protein release 
study to allow further formulation development and optimization.  
  The size of the silica nanoparticles also decreased from 246 ± 2 to 185 ± 2nm in silica sample 
SNPs (Figure S5 to S9, supplementary data) with different homogenizer speeds at fixed time, however, 
increasing homogenization time did not greatly affect the particle size as shown in (Figure S7, 
supplementary data) (184 ± 76 to 173 ± 11 nm). On the other hand, PDI was greatly affected after 
homogenization and simultaneously zeta potential value also increased which helped to increase the 
monodispersed nature of the particles in solution. The PDI at 1000 rpm was 0.34 ± 0.01, but increasing 
homogenizer speed to 10,000 caused the PDI to be reduced to 0.21 ± 0.02. This was evidenced by 
changing from bimodal at the low speed to monomodal at the higher homogenization speed. Zeta 
potential value increased from -27 ± 2 to -35 ± 1 in silica nanoparticles  (Figure S6, supplementary 
data), which indicated that particles stability in solution was increased. It was difficult to carry out 
homogenization beyond 25 min at 10,000 speeds due to bubble formation, therefore homogenizer speed 
of 10,000 with 25 min homogenization time was deemed optimised for further formulation 
development.   
 Overall, the effect of homogenization speed (at fixed time of stirring) and different durations 
(at fixed speed) appeared to be more pronounced on size and PDI of PLGA nanoparticles compared to 
the chitosan and silica nanoparticles as shown in figures S5, S6 and S7, whilst the differences in effect 




3.3 Effect of ultra-sonication  
Figure 3a, illustrates the effect of sonication on particle size in the PLGA, chitosan and silica 
nanoparticles. The results in Figure 3 showed that probe sonication clearly disintegrated the initial 
particles and formed smaller and more monodisperse sizes.  
 
Figure 3 Investigation of (a) effect of ultra-sonication on size of selected optimised blank poly(lactic-
co-glycolic acid)-polyvinyl alcohol (PLGA-PVA), chitosan-sodium tripolyphosphate (TPP) and silica 
(SNPs) nanoparticles and (b) effect of ultra-sonication on zeta potential of selected optimised blank 
poly(lactic-co-glycolic acid)-polyvinyl alcohol (PLGA-PVA), chitosan-sodium tripolyphosphate (TPP) 
and silica (SNPs) nanoparticles (n = 3).  
 
 



















































poly(lactic-co-glycolic acid)-polyvinyl alcohol (PLGA-PVA), chitosan-sodium tripolyphosphate (TPP) 
and silica (SNPs) nanoparticles (n = 3).  
 
Figure 3c: Investigation of effect of sonication on PDI of selected optimised blank poly(lactic-co-
glycolic acid)-polyvinyl alcohol (PLGA-PVA), chitosan-sodium tripolyphosphate (TPP) and silica 
(SNPs) nanoparticles (n = 3). 
 
PDI graph (Figure 3c) for PLGA-PVA formulation showed that within 2 min of probe sonication, the 
particles became monodispersed and PDI decreased subsequently. This finding is consistent with other 
research strategy previously reported [8]. However, further probe sonication beyond 2 min reduced 
particles size more and after 5 min, the PDI values increased significantly (p > 0.05) again while zeta 
potential (Figure 3b) values decreased (p > 0.05). 
The other two PLGA formulations prepared using different surfactants (PLGA-TW and PLGA-PL), 
showed a significant effect (p < 0.05) of sonication on their particles size, PDI and zeta potential values. 
Further, sonication in both formulations caused zeta potential value to be reduced and might be due to 
its effect on the nanoparticles structure and subsequent agglomeration. The results (Figures S10, S11, 
S12, supplementary data) showed relatively small particle agglomeration during a prolonged probe 
sonication and slight increase in zeta potential until 4 min after which no significant (p > 0.05) impact 
was observed in zeta potential and PDI values. It was therefore concluded that the nanoparticles size 
reduced, were monodisperse and stable within 4 min of sonication. These results are expected since the 
high concentration of surfactant (PVA, PL or TW) leads to high collision frequency of NPs, and 
therefore a high probability of agglomeration. Similar observation has been reported for TiO2's NPs 
(Tantra et al. 2015). 
             The average diameter of chitosan nanoparticles was 265 ± 1 nm, PDI at 0.31 ± 0.05 and zeta 

























decreased after sonication, but the particle size reduction rate after 8 min of sonication was not 
significant (p > 0.05). The DLS analysis indicates the reduction of the average particle size from 245 to 
215 nm when ultra-sonication time increased from 2 to 10 min. Zeta potential value in Figure 3b also 
increased while PDI value decreased between 1min and 4min of sonication time. The reduction in size 
of the particles after ultra-sonication was probably related to the depolymerisation of the chitosan 
molecules. This is because the change in the average particle diameter of the nanoparticles was almost 
similar even after changing the ultra-sonication time.  
 There was a high tendency for agglomeration when the silica nanoparticles were prepared using 
the sol-gel synthesis method. According to recent studies [27], other methods used to enhance both 
nano fluid dispersion and stability are inadequate because these procedures only take very dilute volume 
fractions and also depend on the opacity of the particles dispersed. With increased ultra-sonication time 
it was shown that particles size was decreased in sample PLGA 1 to PLGA5 which reduced the extent 
of agglomeration. Unlike PLGA and chitosan, the average particle size (Figure 1A) of the silica 
nanoparticles decreased after ultra-sonication for 6 min, PDI (Figure 1B) also decreased within the same 
time period.  
Unlike homogenization, where PLGA nanoparticles were most affected, probe sonication 
affected the silica nanoparticles compared to the optimised PLGA and chitosan nanoparticles. The silica 
nanoparticles showed significant reduction in particle size below 200nm after 6 minutes of sonication, 
whilst the PLGA and chitosan nanoparticles remained far higher than 200 nm even after 12 minutes of 
probe sonication. This suggests that different energy input affects different chemical nano-structures in 
a different way. 
  
3.4 BSA loading efficiency of nanoparticles 
Figure 4 shows the protein loading and encapsulation efficiencies of selected optimised nanoparticles 
of the different formulations (PLGA, chitosan and silica) investigated. 
In protein based vaccine delivery research for PLGA nanoparticles, the preferred size is 200 to 500nm 
and at this dimension, nanoparticles can easily trigger dendritic cells (DCs), antigen specific T helper 
cells and cytotoxic T lymphocytic cells in order to activate cellular immune response and they can be 
endocytosed by antigen presenting cells (APCs) [28]. Figure 4 showed that blank PLGA-1% PVA 




Figure 4: Bovine serum albumin (BSA) (model protein) loading capacity (LC) and encapsulation 
efficiency (EE) in the formulated poly(lactic-co-glycolic acid) (PLGA), chitosan and silica (SNPs) 
nanoparticles (n = 3). 
 
The same blank formulation showed zeta potential of -17 ± 6 mV and PDI of 0.36 ± 0.05 but after BSA 
loading showed a zeta potential of -28 ± 3 mV and PDI of 0.24 ± 0.04. PLGA-1.5% PVA blank 
nanoparticle had a size of 278 nm but after protein encapsulation this was increased to 319 nm (Figure 
S14 supplementary data). In addition, protein loaded PLGA-PL, PLGA-TW formulations also showed 
differences from blank nanoparticle in terms of size. The value of zeta potential after protein loading 
suggests that most of the PVA based formulations were stable in the colloidal dispersion due to zeta 
potential values near -30 mV (Figure S16). However, the zeta potential values of PLGA-1%TW and 
PLGA-1%PL formulation suggest that these formulations should not be stored in liquid suspension 
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form and but stored in a lyophilized state. The result of protein loading capacity and encapsulating 
efficiency in optimised PLGA-%PVA formulation showed 63% protein loading due to similar surface 
charge for both polymer and surfactant and high particle dispersion. However, the protein loading of all 
formulations were still lower than expected and indicates poor protein encapsulation during the 
nanoparticle preparation procedure. These findings also suggest that a high polymer concentration may 
be required as well as the need to decrease particle size which will increase surface area to help improve 
protein loading.  
For chitosan, encapsulation of protein is largely the consequence of how the cationic chitosan chain 
interacts with protein molecules which have both positive and negatively charged functional groups and 
also hydrophobic regions in an aqueous environment. Some studies [29] suggest that, the encapsulation 
efficiency of protein is high irrespective of the chitosan molecular weight and indicated that the 
entanglement of the protein within the chitosan chain is not effected by their molecular weight.      
The fixed BSA concentration at 0.5mg/ml with formulations prepared with different chitosan 
concentrations (0.1% to 0.4%) showed that loading efficiency (LE) was increased from 68% to 72%, 
similarly loading capacity (LC) also increased from 27 to 48% (Figure S13, supplementary data). After 
protein loading, the particles size also increased from 221 ± 16 to 246 ± 27 for 0.1% to 0.4% (Figure 
S14).      
Profiles of silica nanoparticles encapsulating BSA, LC and LE are summarized in Figure S13 
(supplementary data). The encapsulation of silica-6 sample was 25% due to low yield in the amount of 
nanoparticles formed as confirmed by DLS and SEM images while in sample silica-8, a maximum of 
42% BSA encapsulation was obtained. In addition, the tendency of particle aggregation and 
agglomeration of nanoparticles was higher according to PDI value, though the weight ratio for 
encapsulation between proteins and MSNs was 1:1. Another important factor that affects encapsulation 
of proteins in silica nanoparticles is surface chemistry and pore size. Pore size blocking by surfactant 
would lower amount of protein that could be encapsulated and therefore needs to be optimal. Zeta 
potential value was also analysed before and after encapsulation. All the formulated silica nanoparticles 
had a negative surface charge and zeta potential value remained negative after addition of BSA (Figure 
S16). In sample silica-9, the particles size changed from 176 ± 7 to 201 ± 5 nm after protein loading, 
PDI value also increased from 0.24 ± 0.11 to 0.37 (Figure S15) and zeta potential value changed from 
-33 ± 6 to -43 ± 3 mV. 
Comparing between the three types (synthetic organic, natural organic and inorganic) of nanoparticles, 
the PLGA and silica formulations had negative zeta potential compared to the chitosan which remained 
positive. Further, the silica particles appeared to have higher zeta potential values than the PLGA and 
chitosan particles suggesting the inorganic particles were more physically stable than the organic 
equivalents. This is interesting, given the fact that the silica nanoparticles remained small in size (around 




3.5 Morphology of the nanoparticles by electron microscopy 
The morphology of formulated nanoparticles was determined through the visualization of their 
microscopic appearance using SEM and TEM.  
Figure 5 showed that the PLGA nanoparticles were of spherical shape Figure 5 (A) represents 
PLGA-PVA 1.0% formulation, showing spherically shaped nanoparticles with size range between 200 
nm to 1µm. Figure 5(b) represents PLGA-PVA 1.0% after sonication and showed smooth spherical 
shape but larger particles were also present. Figure 5(c), representing PLGA-PVA1% formulation after 
BSA loading, was spherical in shape and porous with uniform dispersion of particles.  
Figure 5 (d) shows chitosan 0.1% nanoparticles which showed a high number of particles formed but 
with varied sizes. Figure 5(e), represents chitosan 0.1% formulation after sonication and showed 
spherical shape, with size range between 200nm to 1µm and ellipsoidal shapes of some of the particles. 
This probably results, from high speed homogenization and sonication, forming turbulences which 
induce a heterogeneous energy distribution in the emulsion system, which results in some particles 
starting to lose the spherical appearance and becoming irregular in shape. Figure 5(f), representing BSA 
loaded chitosan 0.1% shows that all particles were regularly shaped and size ranged between 200nm to 
1µm and some large particles also appeared. It might be due to the fact that high speed stirring results 
in vigorous particle collisions between them and therefore formation of regular shaped particles. Figure 
5 (g), representing optimised silica 9, showed smooth surface and size range between 200 nm to 1.5µm 
and Figure 4(h), shows silica 9 formulation after sonication, while Figure 5(i) shows corresponding 
BSA loaded silica 9 nanoparticles. SEM images for the other formulations prepared during formulation 





Figure 5: Scanning electron microscopy analysis of poly(lactic-co-glycolic acid) (PLGA), chitosan and 
silica nanoparticles. Image A; blank PLGA nanoparticles, Image B: sonicated blank PLGA 
nanoparticles, Image C; BSA loaded and sonicated PLGA nanoparticles, Image D; blank chitosan 
nanoparticles, Image E; blank sonicated chitosan  nanoparticles, Image F; BSA loaded and sonicated 
chitosan nanoparticles. Image G; blank silica nanoparticles, Image H; sonicated blank silica 
nanoparticles, Image I; BSA loaded silica nanoparticles.  
 
TEM and STEM allow the observation of liquid nanoparticle suspensions and might give an 
accurate idea about nanoparticle shape which allowed the visualization of BSA encapsulation within 
the PLGA nanoparticle. Figure S18 (supplementary data) showed the presence of a dense core in the 
nanoparticle embedded resin block with bright shell which confirms BSA loading within the PLGA 
polymeric matrix. The variations in brightness and contrast reflects the internal characteristic of the 
cross-sections of nanoparticles. In figure S18(a), the polymeric background encapsulating the BSA 
protein showed uniform and moderate brightness and contrast. The BSA-encapsulated areas are 
characterized by the dark colour showing a high contrast with the background. Figure S18(b), showed 
that the particles were closely aggregated with each other after protein encapsulation and Figure S18(c) 
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confirmed that particle sizes were varied but not aggregated with each other. The uniform blank 
polymeric background showed in Figure S18(d) also demonstrated highlighted dark coloured area 
present. These BSA containing nanoparticles showed that the protein occupying areas were intersected 
and were visually porous in structure as confirmed by SEM images. Scanning transmission electron 
microscopy (STEM) image [Figure S18(f)] showed particles are uniformly dispersed but sizes were 
visually variable as confirmed by SEM image.   
The size distribution of protein loaded chitosan-TPP nanoparticles obtained from STEM 
analysis is shown in Figure S19 (supplementary data). From the STEM images it can be observed that, 
the particle size of nanoparticles was slightly smaller than the equivalent size data obtained from DLS 
analysis. This is because DLS measures the hydrodynamic diameter of particles whereas SEM measures 
whole morphology, size and shape of nanoparticles. The STEM data indicates that the protein loaded 
chitosan nanoparticles’ (0.1% to 0.4%) size ranged between 100-200 nm. A homogenous distribution 
of nanoparticles can be observed in Figure S19 (supplementary data) from the STEM analysis, whilst 
the SEM images also showed smooth and spherical shape of nanoparticles. The STEM images in 
Figures S19 showed BSA loaded chitosan-TPP nanoparticles with large particles present along with a 
large number of smaller particles. At high magnification, it was observed that the micron sized particles 
were actually clusters of agglomerated nanoparticles. Therefore, the micron-size images and nano-sized 
image was scanned by STEM with a magnification of 5k and 20k. From Figures S20, S21, S22 and S23 
(supplementary data) for silica-CTAB9 and silica-CTAB10, it can be seen that there was no change in 
the general background of the STEM image (blank and protein loaded) before and after the radiation.  
 
3.6 Attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) ATR-
FTIR analysis was used to determine specific functional groups or chemical bonds in the samples by 
the vibration modes of these bonds when exposed to infrared radiation. The ATR- FTIR spectra 
obtained for pure starting materials is shown in Figure 6a whilst spectra for selected optimised blank 
and BSA loaded PLGA, chitosan and silica nanoparticles are shown in Figure 6b. Detailed ATR-spectra 
for all the formulations prepared as part of formulation development are shown in the supplementary 
data (Figures S24, S25, S26, S27 and S28) The strong band observed in the region between 1650 cm-1 
and 1750 cm-1, can be attributed to the carbonyl group present in the formulated blank PLGA-PVA 
formulation. The broad band at 3300 cm-1 to 3600 cm-1 is attributed to the presence of (OH) group of 
glycolide and lactide copolymer and from moisture content. PLGA-1%PVA BSA loaded nanoparticles 
showed structural modification compared to blank nanoparticle with a major shift observed at 3450 cm–
1. The spectra of BSA loaded and blank PLGA nanoparticle showed all the characteristic peaks at 750-
1250 cm–1(C-C, C=O, -OCH3) and with negligible shift at 3305 cm–1, 3294 cm–1, 2886 cm–1, 2927 cm–
1, 1749 cm–1, 1343 cm–1 and 852 cm–1, which indicated there was no significant chemical structural 
change for blank PLGA during BSA loading. The FTIR spectra of pure BSA compared with the protein 
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loaded nanoparticle showed that the 1600-1800 cm−1 band, indicating C=C stretching, was significantly 
lowered and suggests that BSA was largely incorporated into the nanoparticle matrix.    
ATR-FTIR spectroscopy was also employed to identify any modification that occurred during 
the chemical transformation between chitosan, TPP and BSA. In 0.4% chitosan formulation (Figure 
S26, supplementary data) a peak can be observed at 1412 cm-1, which indicates -NH2 bending vibration 
which might be attributed to the phosphoric group of TPP linked with NH3+ group of chitosan 
suggesting that inter and intra molecular interaction are enhanced in chitosan-TPP nanoparticles. BSA 
loaded 0.1% chitosan formulation showed a sharp peak at 1076 cm-1 corresponding to the stretching 
vibration of the P=O groups in chitosan-TPP nanoparticles.  
   For silica nanoparticles the vibrating band between 400 -1200 cm-1 is attributed to Si-O-Si 
vibrations, and having a shoulder at 1190 cm-1. The spectra of BSA loaded silica nanoparticles 
demonstrates the presence of extra bands at 2985 cm-1 and 2960 cm-1 attributed C-H bonds asymmetric 
and symmetric stretching vibrations, an extra band at 2947 cm-1 attributed to the methyl group connected 
to a nitrogen atom of BSA loaded nanoparticles. It was observed that between 1500 and 1300 cm-1, two 
vibration bands can be distinguished, which can be attributed to BSA loading. The 1451 cm-1 band is 
attributed to the C-H deformation vibration and another band at 1398 cm-1 due to stretching vibrations 









Figure 6a: FTIR spectra of pure starting materials – bovine serum albumin (BSA), poly(lactic-co-
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Figure 6b: ATR-FTIR analysis of blank and bovine serum albumin (BSA) loaded poly(lactic-co-
glycolic acid)-polyvinyl alcohol (PLGA-PVA), chitosan-tripolyphosphate (chitosan-TPP) and silica 
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3.7 X-ray diffraction (XRD) 
The X-ray diffraction patterns of blank and BSA loaded nanoparticles were investigated to confirm the 
physical form (amorphous or crystalline nature) of the nanoparticles and shown in Figures 7a and 7b. 
PLGA-1%PVA showed crystalline nature after BSA was added but with reduced crystallinity and the 
sharp intense peak shown at 24º 2θ might be due to the presence of trehalose in the matrix. Comparing 
BSA loaded PLGA-PVA (Figure S29, supplementary data) nanoparticles with the corresponding blank 
nanoparticles, there was a reduction in intensity and number of peaks after protein loading, which 
indicates reduced crystallinity. Blank PLGA-1.5%PL (Figure S30, supplementary data) nanoparticle 
formulation exhibited reduced crystallinity and most intense peaks occurred at diffraction angle of 24° 
2θ. BSA loaded PLGA-1.5%PL (Figure S30, supplementary data) nanoparticle showed no sharp peak 
and indicates that the trehalose dispersed in the polymer and was possibly converted from crystalline to 
amorphous form after freeze drying. PLGA-1.5%TW (Figure S30, supplementary data) nanoparticle 
formulation showed peaks with similar intensity to the blank nanoparticle which might be due to the 
high amount of trehalose present in blank nanoparticles  in this formulation as discussed above. 




















Figure 7a: XRD-diffractograms of pure starting materials – bovine serum albumin (BSA), 
cetyltrimethylammonium bromide (CTAB), chitosan, polyvinyl alcohol (PVA), poly(lactic-co-glycolic 
acid)(PLGA), trehalose and tripolyphosphate (TPP).  
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Figure 7b: XRD-diffractogram of blank and bovine serum albumin (BSA) loaded poly(lactic-co-
glycolic acid)-polyvinyl alcohol (PLGA-PVA), chitosan and silica (SNPs) nanoparticles.  
 
The pure chitosan was in amorphous state (Figure 7a) but after nanoparticle formation and 
encapsulation of BSA protein, a crystalline phase was observed (Figure 7b). The XRD patterns of BSA 
loaded chitosan-TPP nanoparticles showed a narrow intensity peak at 24°, characterizing the crystalline 
state of all the BSA loaded chitosan-TPP nanoparticles (Figure 7b). This is due to the interaction 
between crystalline TPP and chitosan, but with reduced crystallinity. The positions of the narrow 
intensity  peaks was not shifted  in the BSA loaded nanoparticles (compared to blank) but peak intensity 
reduced after BSA loading suggesting a certain degree of interaction between BSA and chitosan-TPP 
nanoparticles [30]. Hydrogen bonding is formed based on the nanoparticle complexes between the 
nitrogen atoms of BSA protein and H atoms from NH2, NH3+ and P=O groups of chitosan-TPP 
nanoparticles. Several researchers [31][32] also reported a similar phenomenon, with reduction of 
crystalline peaks after protein encapsulation due to interaction between BSA and chitosan. The XRD 
patterns of the other formulated chitosan nanoparticles are shown in Figures S31 and S32. 
Figure 7b, indicates that the conjugated and entrapped forms of the protein are unable to form 
their own crystal lattice inside the polymer and therefore are in amorphous state [33]. These results are 
interesting since in the amorphous state, the molecules are arranged randomly, which results in lower 
energy consumption and dissolution rate is faster, thereby the potential of increasing the protein 
bioavailability.     
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The XRD pattern of silica nanoparticles showed three considerable peaks corresponding to 
lattice spacing of 20.631, 21.403 and 21.675 (Figure 7b) which compares very well with  XRD 
diffractogram  for SiO2. Figure (S33, S34, supplementary data) shows the XRD patterns of silica 
nanoparticle samples Silica6, Silica7, Silica8, Silica9, and Silica10. The results show that all BSA 
loaded and blank silica samples were relatively amorphous in nature and results are consistent with that 
reported by others (Liao et al., 2014). 
 
3.7 In vitro protein release study: 
In vitro protein release study was performed in phosphate buffer (pH 7.4) in order to determine the 
capability of optimised BSA loaded nanoparticles to release encapsulated protein and Figure 8 shows 
the dissolution profiles for the selected optimised formulation for each type of nanoparticle being 
compared. Initial burst release (Figure 8) occurred for PLGA-1%PVA nanoparticles with more than 
25% of protein released within 4 hrs. On the other hand, for PLGA-1.5% PVA (Figure S35, 
supplementary data) nanoparticles, about 20% protein was released after 6 hrs. The release patterns of 
PLGA-1% PVA (Figure 89) and PLGA-1.5% PVA formulation were very similar with an initial burst 
release within the first 2 hrs and a sustained release pattern until 48 hrs, which is characteristic of PLGA-
based nanoparticles [35]. 
 
Figure 8: In-vitro BSA release study from poly(lactic-co-glycolic acid)-polyvinyl alcohol (PLGA-PVA) 
(PLGA-PVA), chitosan and silica (SNPs) nanoparticles (n = 3). 
 
On the other hand, PLGA-1%PL (Figure S35, supplementary data) nanoparticles showed more than 






























data) nanoparticles showed more than 40% protein release after 12 hrs. The initial burst release of 
protein from the nanoparticles may be explained by the BSA present on nanoparticle surface after which 
the encapsulated BSA was released over a longer time period and achieving sustained release pattern. 
In this study, it was shown that most of the nanoparticle formulations released 40 to 50% of protein 
within 24 hrs in a sustained manner. For example, the cumulative amount of protein released from the 
PLGA-1%PL (Figure S35, supplementary data) nanoparticles within 24 hrs was approximately 50% 
whilst PLGA-1%TW (Figure S35, supplementary data) was about 40%.  
PVA and PL could possibly delay the degradation of PLGA by neutralizing the acidity 
generated during polymer degradation and able to prevent unexpected interaction between polymer and 
protein, resulting in slow release of BSA from the polymer matrix [2136]. It is possible that higher 
amounts of surfactant with low amount of polymer in PLGA-1%PL nanoparticles and subsequent 
reduction in particle size of 192 nm and higher PDI of 0.31 (Figure S14, supplementary data) resulted 
in higher protein release due to increase in the surface area of the nanoparticle. Biodegradability and 
biocompatibility of PLGA nanoparticle is one of the most important properties for delivering 
biologically active molecules such as protein, peptide and small molecule drugs. Several studies have 
shown that, encapsulation of biologically active molecules into PLGA nanoparticles increased their 
bioavailability and reduced toxicity [37]. Sustained release of proteins from nanoparticle is imperative 
as that could provide long term therapeutic effect against diseases [38]. In some studies, it has been 
shown that high burst release especially within 24 hrs is not preferred since it causes low T-cell response 
and antigenic protein release from nanoparticle in low burst fashion may achieve a better vaccine 
activity and immune response [39]. 
Nearly 68% loaded protein was completely released from chitosan nanoparticles in 48 hrs. 
Formulation 0.1% showed an initial burst release occurring within 2 hrs, with more than 19% of protein 
released within this time. Protein release for formulation 0.2% to 0.4% (Figure S36, supplementary 
data) increased sharply initially and slowed down up to 48 hrs. The highest protein released obtained 
from formulation 0.2%, 0.3% and 0.4% (Figure S36, supplementary data) after 48 hrs was 62%, 64% 
and 52% respectively. As the concentration of chitosan increased the viscosity of the solution was 
increased which could result in strong particle walls, resulting in lower swelling ability, which therefore 
reduces the rate of protein release.  In addition, there are electrostatic interaction between chitosan-TPP 
and BSA that could affect the percentage released. For smaller size nanoparticles, a greater percentage 
of BSA was released than from large particles because small particles have a greater surface to volume 
ratio, and the mechanism at this stage is diffusion of BSA protein inside the nanoparticles due to the 
concentration gradient.  
 Figure 8 also shows that the release of proteins from silica nanoparticles prepared from TEOS 
and CTAB. Large amount of BSA released was observed from sample silica 10 (Figure S37, 
supplementary data). The profile for silica and PL formulation showed that 17% BSA was released 
within 30 min and after 4 hrs almost 43% of BSA was released. This might possibly be due to less 
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formation of nanoparticles and it is also possible that lower protein might be encapsulated into the 
nanoparticles due to the excess amount of surfactant which could block nanoparticles pore and prevent 
protein adsorption by nanoparticles. After 48 hrs, 64% BSA released was observed for silica 6 sample.    
Overall, though the nanoparticles were prepared from three different starting materials (synthetic 
organic, natural organic and inorganic), all three selected optimised formulated nanoparticles (PLGA, 
chitosan and silica) showed similar sustained release profiles (Figure 8). This is interesting, and suggests 
that the properties of the drug and the medium environment, play an important role in determining drug 
release characteristics from nanoparticles prepared from different materials, however, further 
investigation will be required in this regard. 
 
4. Conclusions  
This research aimed to formulate and compare the functional performance characteristics of 
nanoparticles prepared from three different starting materials (organic and inorganic) and investigate 
factors that affect the achievement of optimal size and high protein encapsulation for potential mucosal 
vaccination. The results demonstrated that the surfactant: polymer ratio, homogenizer speed and 
duration (time) of homogenization, greatly influenced nanoparticle size and PDI. The mean particle size 
of formulated optimised PLGA nanoparticles was smaller than that reported by other researchers and 
noted to be optimal for protein encapsulation. In terms of zeta potential and size, PLGA-1% PVA and 
PLGA-1%PL were optimal formulations for further protein encapsulation study. Both formulations 
exhibited sustained release of encapsulated protein but also showed incomplete release of protein from 
nanoparticle over a period of 40 hrs. Ionotropic gelation technique was a suitable technique for 
preparing chitosan-TPP nanoparticles with a nano-size range and also successfully protein loaded. The 
amount of chitosan and BSA had great effect on the protein loading, encapsulation efficiency, size and 
zeta potential. For the inorganic nanocarriers, the CTAB based silica nanoparticles were porous before 
protein loading and this porous structure enabled successful loading of protein. Silica nanoparticles 
prepared from 0.8% CTAB with 2ml TEOS solution was considered optimised formulation according 
to protein release profile, morphology and nanoparticles stability and was considered for further study. 
Finally, the optimised PLGA, chitosan and silica nanoparticles exhibited similar sustained BSA release 
profiles and the rate of release from all three type of nanoparticles was not significantly different, 
suggesting, that factors such as the properties of the protein and the dissolution may play an important 
role in drug release from these matrices. 
 
Future Perspective: 
Though very few nanoparticle based formulations have reached the market, the interest in these versatile 
formulations will continue to increase, driven mainly by the advances in biotechnology and new 
biomacromolecules such as peptides, proteins, nucleotides, and even stem cells, that require effective 
protection afforded by encapsulation within nanoparticulate formulations, due to their poor stability. 
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Furthermore, the need for targeting such biomacromolecules to specific sites of action, including cancer, 
vaccine delivery as well as avoiding destructive enzymes, will continue to drive an interest in 
nanoparticles. This is because nanocarriers have the ability to allow surface functionalisation, which 
enhances controlled release in time and site specific ways. Finally, the need to avoid painful injections, 
especially in the paediatric and geriatric populations will drive interest in alternative formulations to 
allow easy oral administration, as is the case for oral mucosal vaccination, which will also avoid first 





 Nano carriers can help to deliver therapeutic proteins via the oral route. This study aimed to 
develop compare nanocarriers obtained from three different types of materials using BSA as a 
model protein antigen.  
 This is the first study that systematically compares nanoparticles obtained from synthetic 
organic (PLGA), natural organic (chitosan), and inorganic starting materials and 
simultaneously investigate the effect of process and formulation variables on the performance 
characteristics of the resulting nanoparticles for potential protein delivery. 
 
Methods 
 PLGA nanoparticles were prepared by solvent emulsification evaporation and double emulsion, 
chitosan nanoparticles using inotropic gelation and silica nanoparticles by sol-gel synthesis 
process. Finally, BSA was loaded into selected optimised PLGA, chitosan and silica 
nanoparticles.  
 The nanoparticles were characterised for size, zeta potential and PDI using DLS including the 
effect of formulation and process parameters, while protein loading, encapsulation and release 
were determined using Bradford assay. Physical properties of starting materials and formulated 
nanoparticles were characterised using SEM, TEM, STEM, XRD, FTIR and in vitro drug 
release for BSA loaded formulations. Finally, the functional properties of the 3 different 
nanoparticles (PLGA, chitosan and silica) were compared. 
  
Effect of concentration of polymer, silica and surfactant on particle properties.   
 The amount of surfactant and polymer affected the particle size, PDI and zeta potential of 
PLGA nanoparticles. For chitosan nanoparticles, the particle size, PDI and zeta potential 
increased with increasing chitosan concentration. Monodisperse particles with uniform size was 
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observed for the silica nanoparticles prepared with CTAB concentration of 0.9% and was 
chosen as optimum concentration for protein loading. 
 
Effect of homogenization  
 Faster stirring produced more stable PLGA particles based on the zeta potential. For a fixed 
stirring speed, the particle size decreased and zeta potential increased with increasing 
homogenization time. 
 For chitosan nanoparticles, increasing homogenization speed from 1000 to 7000 rpm reduced 
size from 325 to 277nm while effect of homogenisation time was inconclusive.  
 The size of the silica nanoparticles decreased from 246 to 185nm with increasing homogenizer 
speeds, however, increasing homogenization time did not significantly affect the particle size. 
However, PDI decreased and zeta potential increased with homogenisation, which increased 
stability and monodispersed nature of the nanoparticle suspension. 
 Generally, the effect of homogenization appeared to be more pronounced on size and PDI of 
PLGA nanoparticles compared to the chitosan and silica nanoparticles whilst the differences in 
effect on zeta potential between the three types of formulations was less pronounced. 
 
Effect of ultra-sonication  
 Within 2 min of probe sonication, PLGA particles became monodispersed and PDI decreased 
subsequently optimum sonication time determined at 4 min. For chitosan nanoparticles average 
diameter of chitosan nanoparticles decreased after sonication, but the particle size reduction 
rate after 8 min of sonication was not significant. Zeta potential also increased while PDI values 
decreased between 1 and 4 min of sonication time. With increased ultra-sonication time silica 
particles size decreased which reduced the extent of agglomeration.  
 Unlike homogenization, where PLGA nanoparticles were most affected, probe sonication 
affected the silica nanoparticles more compared to the optimised PLGA and chitosan 
nanoparticles. The silica nanoparticles showed significant reduction in particle size below 
200nm after 6 minutes of sonication, whilst the PLGA and chitosan nanoparticles remained far 
higher than 200nm even after 12 min of probe sonication.  
  
BSA loading efficiency of nanoparticles 
 All the optimised nanoparticles fell within the preferred size range for protein based vaccine 
delivery which is 200 to 500nm. 
 Blank PLGA-PVA nanoparticle which had an original size of 244 nm, increased in size to 292 
nm after protein loading. For chitosan nanoparticles, changing chitosan concentrations (0.1% 
to 0.4%) increased EE from 68% to 72%, and LC from 27 to 48%. After protein loading, the 
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particles size also increased from 221 to 246nm. All silica nanoparticles had a negative surface 
charge and zeta potential increased and remained negative after BSA loading and size also 
increased from 176 to 201nm. 
 PLGA and silica formulations had negative zeta potential whilst chitosan remained positive. 
Silica nanoparticles showed higher zeta potential values than the PLGA and chitosan suggesting 
the inorganic particles were more physically stable than the organic equivalents. 
 
Morphology of the nanoparticles by electron microscopy 
 PLGA nanoparticles were of spherical shape with size range between 200 nm to 1µm 
Chitosan 0.1% nanoparticles showed a high number of particles formed but with varied sizes 
ranging between 200nm to 1µm. Optimised silica 9, showed smooth surface and size range 
between 200nm to 1.5µm. 
 TEM and STEM confirmed the encapsulation of BSA within the optimised PLGA, chitosan 
and silica nanoparticles. 
 
In vitro protein release study  
 The nanoparticles were prepared from three different starting materials (synthetic organic, 
natural organic and inorganic), all showed similar sustained release profiles.  
 This suggests that the properties of the drug and the medium environment, play an important 
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